Iberdomide
- Generic Name
- Iberdomide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O5
- CAS Number
- 1323403-33-3
- Unique Ingredient Identifier
- 8V66F27X44
- Background
Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.
- Associated Conditions
- -
- Associated Therapies
- -
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Omar Nadeem, MD
- Target Recruit Count
- 49
- Registration Number
- NCT06518551
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT06465316
- Locations
- 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Thomas Martin, MD
- Target Recruit Count
- 38
- Registration Number
- NCT06348108
- Locations
- 🇺🇸
University of Calfornia, San Francisco, San Francisco, California, United States
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 88
- Registration Number
- NCT06232044
Iberdomide Vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 411
- Registration Number
- NCT06216158
- Locations
- 🇩🇪
Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie, Berlin, Germany
🇩🇪Helios Klinikum Berlin-Buch, Berlin, Germany
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 87
- Registration Number
- NCT06215118
- Locations
- 🇨🇦
CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec, Canada
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT06179888
- Locations
- 🇺🇸
Mission Cancer and Blood - Ankeny, Ankeny, Iowa, United States
🇺🇸Iowa Methodist Medical Center, Des Moines, Iowa, United States
🇺🇸Mission Cancer and Blood - Des Moines, Des Moines, Iowa, United States
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 111
- Registration Number
- NCT06121843
- Locations
- 🇺🇸
University Of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Local Institution - 0002, Phoenix, Arizona, United States
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT06107738
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT05899738
- Locations
- 🇺🇸
Local Institution - 0001, Daytona Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.